Skip to main content

Advertisement

Table 5 Expression of Smurf2 relative to ER, PR and HER2 status in non-malignant and malignant breast tumors

From: Regulation of CNKSR2 protein stability by the HECT E3 ubiquitin ligase Smurf2, and its role in breast cancer progression

  Non-Malignant Malignant P-value
(n = 22) (n = 62)  
Smurf2 ER    
no/mild no/mild 14(63.64%) 6(9.68%) < 0.001
no/mild mod/intense 2(9.09%) 0(0.00%)  
mod/intense no/mild 2(9.09%) 38(61.29%)  
mod/intense mod/intense 4(18.18%) 18(29.03%)  
Smurf2 PR    
no/mild no/mild 9(40.91%) 4(6.45%) < 0.001
no/mild mod/intense 7(31.82%) 2(3.23%)  
mod/intense no/mild 1(4.55%) 41(66.13%)  
mod/intense mod/intense 5(22.73%) 15(24.19%)  
Smurf2 HER2    
no/mild no/mild 12(54.55%) 2(3.23%) < 0.001
no/mild mod/intense 4(18.18%) 4(6.45%)  
mod/intense no/mild 4(18.18%) 25(40.32%)  
mod/intense mod/intense 2(9.09%) 31(50.00%)